phloretin has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JH | 1 |
| Chu, SC | 1 |
| Gramlich, JL | 1 |
| Pride, YB | 1 |
| Babendreier, E | 1 |
| Chauhan, D | 1 |
| Salgia, R | 1 |
| Podar, K | 1 |
| Griffin, JD | 1 |
| Sattler, M | 1 |
1 other study available for phloretin and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species.
Topics: Benzamides; Cell Line; Cell Line, Tumor; Cell Transformation, Neoplastic; Deoxyglucose; Enzyme Activ | 2005 |